DECLARE-TIMI 58
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Doente / População Intervenção / Exposição Comparação Desfecho
In 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
N
17 160
Desenho
Double-blind RCT
Desfecho
CV death/HF hospitalisation and MACE (co-primary)
Relevância
2
ResultadoCV death or HF hospitalisation HR 0.83; MACE not significantly reduced.
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357. 10.1056/NEJMoa1812389
Discussão e crítica
The largest SGLT2i outcomes trial, with the most primary-prevention patients — benefit was mainly heart-failure prevention rather than atherothrombotic events.